Filing Flows › Sarepta Therapeutics (SRPT) › Capital expenditures
Sarepta Therapeutics (SRPT) capital expenditures by quarter
Sarepta Therapeutics' capital expenditures were $2.9M in Q3 2026 (third quarter 2026), +429% from Q2 2026. Over the last 4 quarters it ranged from $555K (Q2 2026) to $31.8M (Q2 2025).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $2.9M | +429% | — |
| Q2 2026 | $555K | -85% | -98% |
| Q4 2025 | $3.6M | -89% | — |
| Q2 2025 | $31.8M | — | — |
Q3 2026 at a glance
Sarepta Therapeutics, Q3 2026: revenue $381M (-4% year over year), operating margin -2.4%, net loss $28.5M, operating cash flow $60.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Sarepta Therapeutics' capital expenditures?
Sarepta Therapeutics' capital expenditures were $2.9M in Q3 2026 (third quarter 2026), +429% from Q2 2026.
How has Sarepta Therapeutics' capital expenditures changed?
Over the last 4 quarters it ranged from $555K (Q2 2026) to $31.8M (Q2 2025).